Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy.

Dawicki, Wojciech; Allen, Kevin J H; Garg, Ravendra; Geoghegan, Eileen M; Berger, Mark S; Ludwig, Dale L; Dadachova, Ekaterina

Dawicki, Wojciech; Allen, Kevin J H; Garg, Ravendra; Geoghegan, Eileen M; Berger, Mark S; Ludwig, Dale L; Dadachova, Ekaterina.

Afiliação

Dawicki W; College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.
Allen KJH; College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.
Garg R; College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.
Geoghegan EM; Actinium Pharmaceuticals, New York, NY, USA.
Berger MS; Actinium Pharmaceuticals, New York, NY, USA.
Ludwig DL; Actinium Pharmaceuticals, New York, NY, USA.
Dadachova E; College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.

Oncotarget ; 11(39): 3571-3581, 2020 Sep 29.

Article em En | MEDLINE | ID: mdl-33062193

Palavras-chave

131Iodine; 177Lutetium; adoptive cell therapy; anti-CD45 targeted lymphodepletion; radioimmunotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google